Mobiele menu

The (cost-) effectiveness of a combined strategy for smoking cessation: early prevention of the development of COPD in smokers who are at risk

Projectomschrijving

Verslagen


Samenvatting van de aanvraag

Chronic Obstructive Pulmonary Disease (COPD) is now the third most common cause of death in the Netherlands and is continuing to increase in both prevalence and mortality. Because the main cause of the disease is exposure to cigarette smoke (approximately 90% of the cases is caused by smoking cigarettes), deterioration of the lung function can be prevented if those smokers who are at risk for developing COPD can be detected before they actually develop COPD and help them to stop smoking. However, smokers face many difficulties in their efforts to stop smoking. According to the ASE-model, successful smoking cessation depends on the right combination of attitude, social influence and self-efficacy. Clinical research suggests that, the use of non-nicotine pharmacotherapy (i.e. bupropion and nortriptyline) in combination with counseling is the most effective strategy to help people stop smoking. In a randomised controlled clinical trial, we will compare the effects of bupropion to both placebo and nortriptyline, which is far less costly than bupropion. Two-hundred and twenty-five smokers who are at risk for developing COPD and who are motivated to stop smoking, will receive medication (or placebo) in combination with a structured intervention for smoking cessation (i.e. the Minimal Intervention Strategy [MIS]).

Onderwerpen

Kenmerken

Projectnummer:
22000111
Looptijd: 100%
Looptijd: 100 %
2002
2005
Onderdeel van programma:
Projectleider en penvoerder:
Verantwoordelijke organisatie:
Maastricht Universitair Medisch Centrum+